Chelsea Place Johnson is a senior associate focusing on new company formation across areas of unmet medical need. Prior to joining Atlas Venture in 2019, Chelsea was a member of the Tango Therapeutics founding team, working in business development for the synthetic lethality-focused oncology company. Prior to Tango, Chelsea was a senior associate at Third Rock Ventures where she helped build multiple new biotech companies including Tango.
Chelsea obtained her PhD from the Biological and Biomedical Sciences program at Harvard University where she received the Ruth L. Kirschstein National Research Service Award. Her doctoral work in the lab of Dr. Levi Garraway focused on genomic and functional genomic studies of uveal melanoma. Chelsea received a BA in biology from Dartmouth College and was elected Phi Beta Kappa. Chelsea spends her free time with her husband and son, ideally outside, where she enjoys golf, skiing, and exploring.